Celgene Corp

Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.

Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.

In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.

Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.

Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.

On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.

Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.

Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.

On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.

For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.

In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.

Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

Of the 30 analysts covering Celgene in May, 15 analysts rated the stock a “buy” or higher, and 14 analysts gave Celgene a “hold” rating.

In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.

Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

Celgene’s Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in US, Japanese, EU, and other markets.

Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.

Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.

The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.

AbbVie (ABBV) expects Imbruvica to contribute ~$3.3 billion in revenue in 2018, including $2.7 billion worth of sales contributions from the US market.

According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.

AbbVie (ABBV) expects Humira to report year-over-year (or YoY) growth in its US market sales in the range of 13%–14% in 2018.

In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.

Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

In 1Q17, 2Q17, and 3Q17, Celgene (CELG) generated revenues of $2.96 billion, $3.27 billion, and $3.29 billion, respectively.

On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.

In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $410 million, $490 million, and $556 million, respectively.

In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.

In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

In its 3Q17 earnings conference call, AbbVie raised its fiscal 2017 adjusted diluted EPS (earnings per share) guidance from $5.44–$5.54 to $5.53–$5.55.

AbbVie (ABBV) is currently focused on advancing the research programs for its late-stage immunology assets, Upadacitinib and Risankizumab.